arrow
J

Jorja Braden

the university of sydney
H指数:7
被引数:115

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Longitudinal Analysis Reveals Dynamic Changes in Histopathologic Features in Responders to Neoadjuvant Treatment in a Stage III BRAF-Mutant Melanoma Cohort

纵向分析揭示了在III期BRAF突变黑色素瘤队列中,对新辅助治疗有应答者的组织病理学特征发生动态变化。

2025-05-100
PRE
Concurrent BRAF targeted therapy (TT) with dabrafenib and trametinib and anti-PD-1 agent pembrolizumab (PD1) increased B cell signalling and inflammatory pathways more effectively than when given sequentially or with anti-PD-1 alone

与序贯给药或仅使用抗PD-1药物相比,同时使用达拉非尼和曲美替尼的BRAF靶向治疗(TT)以及抗PD-1药物帕博利珠单抗(PD1)更能有效增强B细胞信号通路和炎症通路。

2024-09-010
PRE
Neoadjuvant pembrolizumab plus lenvatinib in resectable stage III melanoma patients (pts) (NeoPele): Analysis of the peripheral immune profile correlated to pathological response

新辅助培美曲塞联合仑伐替尼在可切除III期黑色素瘤患者(pts)中的应用(NeoPele):与病理反应相关的外周免疫谱分析

2024-09-010
PRE
Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases

单独Anti-PD-1或联合anti-CTLA-4治疗晚期黑色素瘤肝转移患者

2024-07-011
PRE
The association between melanoma liver metastases (mets) and the systemic anti-tumor immune profile
2023-04-040
PRE
NeoTrio - Optimal neoadjuvant (NAT) sequencing of anti-PD-1 and BRAF targeted therapy (TT) in BRAF mutant stage III melanoma: Results of histopathological analysis
2022-09-011
PRE